Ornella Pagliano

发表

Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients

J. Badger, D. Davar, A. Dzutsev, 2021, Science.

T Cells Induced by Melanoma Vaccines + CD 8 Specific − PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2014 .

Microenvironment and Immunology PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen – Speci fi c CD 8 þ T Cells Induced by Melanoma Vaccines

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2014 .

PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.

Hong Wang, Joe-Marc Chauvin, Ornella Pagliano, 2013, Cancer research.

Identification of a 17β-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide

J. Shabanowitz, E. Appella, D. Hunt, 2009, Cancer Immunology, Immunotherapy.

Tim-3 mediates T cell trogocytosis to limit antitumor immunity

Simon C Watkins, D. Davar, Joe-Marc Chauvin, 2022, The Journal of clinical investigation.

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.

D. Davar, Joe-Marc Chauvin, Carmine Menna, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1

J. Badger, D. Davar, A. Dzutsev, 2022, Nature Medicine.

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2015, The Journal of clinical investigation.

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.

Ornella Pagliano, J. Kirkwood, H. Zarour, 2012, Cancer research.

Microenvironment and Immunology CD 8 þ T Cells Speci fi c for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1

Ornella Pagliano, J. Kirkwood, H. Zarour, 2012 .

IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells.

Joe-Marc Chauvin, Ornella Pagliano, J. Kirkwood, 2015, Cancer research.

IL 10 and PD-1 Cooperate to Limit the Activity of Tumor-Speci fi c CD 8 þ T Cells

Joe-Marc Chauvin, Ornella Pagliano, J. Kirkwood, 2015 .

Melanoma and immunotherapy bridge 2015

Andrew J. Park, David C. Smith, A. Hauschild, 2016, Journal of Translational Medicine.

CD226 opposes TIGIT to disrupt Tregs in melanoma.

D. Davar, Joe-Marc Chauvin, Carmine Menna, 2018, JCI insight.

303 Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): final results

D. Davar, Joe-Marc Chauvin, R. DeBlasio, 2020 .

IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma

D. Davar, Joe-Marc Chauvin, R. DeBlasio, 2020, Clinical Cancer Research.

Phase IB study of pembrolizumab (Pembro) and pegylated-interferon alfa-2b (Peg-IFN) in advanced melanoma (MEL).

D. Davar, Joe-Marc Chauvin, Ornella Pagliano, 2016 .

Abstract IA38: Manipulating the gut microbiome to improve immunotherapy of melanoma

J. Badger, D. Davar, Carmine Menna, 2019, Microbiome and Metabolism.

Study of anti-PD-1 antibody pembrolizumab and pegylated-interferon alfa-2b (Peg-IFN) for advanced melanoma.

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2015 .